Pain After Root Canal Obturation With Sealer Containing or Not 1% Enoxolone

NCT ID: NCT03874949

Last Updated: 2019-09-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

95 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-02

Study Completion Date

2019-08-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to assess the efficacy of a zinc oxide eugenol sealer containing Enoxolone, a non-steroidal anti inflammatory drug (NSAID) on the pain relief after endodontic treatment.

The study design is a multicenter, doubled blinded randomized controlled trial. The comparator is the equivalent zinc oxide eugenol sealer without NSAID (allocation ratio is 1:1). The conventional endodontic treatment, using gutta percha and sealer, is done. Patients assess their pain for 7 days after permanent root obturation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Root Canal Obturation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Subject will be randomized in a 1:1 allocation ratio between the two treatment groups.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SEALITE Regular

zinc oxide eugenol sealer

Group Type ACTIVE_COMPARATOR

SEALITE Regular

Intervention Type DEVICE

Patients are treated with SEALITE Regular sealer (zinc oxide eugenol sealer). The SEALITE Regular powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control.

SEALITE Ultra

zinc oxide eugenol sealer containing 1% Enoxolone (NSAID)

Group Type EXPERIMENTAL

SEALITE Ultra

Intervention Type DEVICE

Patients are treated with SEALITE Ultra sealer (zinc oxide eugenol sealer containing 1% Enoxolone).

The SEALITE Ultra powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SEALITE Regular

Patients are treated with SEALITE Regular sealer (zinc oxide eugenol sealer). The SEALITE Regular powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control.

Intervention Type DEVICE

SEALITE Ultra

Patients are treated with SEALITE Ultra sealer (zinc oxide eugenol sealer containing 1% Enoxolone).

The SEALITE Ultra powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male or female aged from 18 to 70 years,
* patient requiring root canal treatment on permanent mature teeth (single rooted teeth, premolar or molar),
* Informed consent signed,
* Patient with social protection.

Exclusion Criteria

* root canal retreatment,
* root canal treatment on an immature tooth,
* calcified root canal assessed radiographically,
* Patient with one or more documented contraindication to endodontic treatment,
* Patient who takes regular analgesic or anti-inflammatory therapy for another pathology,
* Known allergy to NSAID or to one component of the sealer formula,
* Participation to another clinical trial at the same time,
* known pregnancy or lactation,
* Patients with legal protection.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Slb Pharma

OTHER

Sponsor Role collaborator

ACTEON Group

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hugues Colombel, MD

Role: PRINCIPAL_INVESTIGATOR

Private dental practice

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cabinet dentaire

Rennes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SEAU

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Clinical Efficacy of AH Plus Bioceramic Sealer
NCT05763420 ENROLLING_BY_INVITATION NA